Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00813722
Other study ID # PROMEPA
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received December 17, 2008
Last updated December 19, 2008
Start date March 1999
Est. completion date June 2009

Study information

Verified date December 2008
Source University of Sao Paulo
Contact n/a
Is FDA regulated No
Health authority Brazil: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the importance of providing guidelines to patients via active telephone calls in blood pressure control and in the discontinuation of treatment among hypertensive patients. Hypertensives (N = 354) who could receive telephone calls to be reminded of the dates of their medical appointments and to be instructed about hypertension were distributed into two groups: a) "uncomplicated" - hypertensives with no other concurrent diseases; and b) "complicated" - severe hypertensives (mean diastolic ≥ 110 mm Hg with or without medication) or comorbidities. All patients, except those excluded (n=44), were open block randomized to follow two treatment regimens: "traditional" or "current" and to receive active telephone calls ("phone calls" group) or not to receive telephone calls ("no phone calls" group).


Description:

To evaluate the importance of providing guidelines to patients via active telephone calls for blood pressure management and the discontinuation of treatment in hypertensive patients, using two treatment regimens with low-dose medications, which were offered for free to avoid the influence of the financial factor. We opted for a regimen called "traditional" based on diuretics and beta-blockers, and another one called "current" treatment based on the angiotensin II antagonist and calcium channel blocker.

Patients and Methods The patients studied were those with essential hypertension who could receive telephone calls to be reminded of the dates of their medical appointments and to receive guidance about hypertension; patients were of both genders, from any ethnic background, over 18 years old and with body mass index below 40 kg/m2, and were enrolled in the study after signing a free and informed consent term. The study was approved by the Ethics Committee of the Board of Directors in the General Hospital at the São Paulo University School of Medicine.

Exclusion criteria were patients with blood pressure < 140/90 mm Hg without antihypertensive medication, pregnant women or nursing mothers, patients with secondary hypertension, white-coat hypertension with systolic pressure ≥ 140 mm Hg and/or diastolic pressure ≥ 90 mm Hg at the doctor's office and awake mean systolic pressure < 135 mm Hg or awake mean diastolic pressure < 85 mm Hg without antihypertensive medication, malignant hypertension, presence of liver dysfunction evidenced by the patient's clinical history or by one of the liver function tests with levels twice the normal values (alkaline phosphatase, total bilirubin, aspartate aminotransferase), patients with clinical conditions that might interfere with the total conformity with the study or those who might have increased risk for participating in the study, patients with previous history of hypersensitivity reaction to the study medications, patients with a history of alcoholism, drug abuse or mental disorders that might invalidate the free and informed consent or limit the patient's ability to meet the protocol rules, patients who had participated in any other studies involving investigational drugs or drugs already marketed within the previous month, before enrollment in this study or concomitantly with this study.

Measurement of blood pressure was performed five times by the nursing staff in right upper limb, with patient sitting, using a cuff of appropriate size to the arm and a validated automatic oscillometric device (Dixtal, DX 2710, São Paulo, Brazil) The mean of the last two measurements was calculated and recorded as long as the difference between these measurements was less than 4 mm Hg. If after the 5 measurements the difference between the last two ones was higher than 4 mm Hg, the measurement was repeated until the difference between the two measurements was less than 4 mm Hg.

The diagnosis of hypertension was made when the mean values of the last two measurements were: systolic pressure ≥ 140 mm Hg and/or diastolic pressure ≥ 90 mm Hg with or without medication in the initial visit (Visit 0). Patients who were receiving antihypertensive medication at the initial visit and had systolic pressure < 140 mm Hg or diastolic pressure < 90 mm Hg were re-evaluated 8 weeks after discontinuation of their medication and introduction of placebo, and they were included in the study when the mean values were systolic pressure ≥ 140 mm Hg and/or diastolic pressure ≥ 90 mm Hg.

All the patients underwent Ambulatory Blood Pressure Monitoring (ABPM) performed with a validated oscillometric device (SpaceLabs 90207, SpaceLabs Inc, Richmond, WA, USA) , 5 weeks after start of the placebo to eliminate the cases of patients with white-coat hypertension and in patients who did not receive placebo to identify the white coat effect.

Patients were assigned to two groups: a) "uncomplicated" - composed of hypertensive patients without complications and without other concurrent diseases; and b) "complicated", including patients with severe hypertension (mean diastolic pressure > 110 mm Hg with or without medication) or comorbidities such as diabetes mellitus 7, renal failure (serum creatinine > 1.4mg/dL), coronary insufficiency, congestive heart failure or prior history of cerebrovascular accident.

All patients, from both the complicated and the uncomplicated group, were open block randomized to receive active telephone calls ("phone calls" group) or not to receive telephone calls ("no phone calls" group) and to follow two treatment regimens: "traditional" and "current".

Thus, after the first visit and randomization, patients from the "phone calls" group were invited to enroll by telephone in the program called "Biosintética Assistance" supported by Biosintética Laboratory. The patients who subscribed started receiving active telephone calls from appropriately trained operators as well as magazines with health-related information, which were sent periodically by mail. There were 6 contacts by telephone during the study. The patient was reminded to attend the next visit; he/she received instructions about hypertension as well as any necessary clarifications. All the patients randomized to the "phone calls" group were invited to attend occasional informative lectures with the participation of a multidisciplinary team.

At the initial stage of treatment, the "uncomplicated" group received, after 8 weeks of treatment with placebo, one of the following treatment regimens: a) "traditional" treatment with hydrochlorothiazide 6.25 mg 2x/day and atenolol 25 mg 2x/day; and b) "current" treatment with losartan 25 mg 2x/day and amlodipine 2.5 mg 2x/day. If blood pressure could not be controlled during the visits, the medications had their doses doubled or another antihypertensive was added. The "complicated" group did not undergo the treatment period with placebo and was randomized to receive "traditional" or "current" drug regimens similar to the ones administered to the "uncomplicated" group, considering the specificity of each condition. The addition of other antihypertensive agents in the "uncomplicated" group, as well as the specificities of regimens of patients in the "complicated" group, were performed according to the guidelines from the V Brazilian Guidelines on Arterial Hypertension. 5 All the patients were instructed to take the medication every day at 7:00 am and 7:00 pm, with a variation of up to one hour. All the medication necessary for 12 months of treatment was supplied to the patients by the physician at the end of the visit in sufficient amount at no cost until the next visit, in order to eliminate the financial factor in this analysis. Patients were instructed to bring the remaining pills during their subsequent visit to be counted by the nursing staff, without the patients' knowledge of this procedure.

Doctors' visits, preceded by the nursing staff visit, took place every 8 weeks for 56 weeks with measurements of blood pressure, heart rate and weight. The weight was checked with the patient wearing light clothes and barefoot on a scale (model 2096PP, Toledo do Brasil, São Paulo, SP, Brazil).

Study withdrawal was characterized by non-attendance to the medical visit up to 3 months after the scheduled date. The patients who returned within 3 months after the scheduled date would continue in the study and be evaluated in an unscheduled visit.

The tests performed during the treatment with placebo and after 40 weeks of active treatment included: fasting glucose, urea, creatinine, total cholesterol, fractions of cholesterol, triglycerides, uric acid, total bilirubin, CPK, Na+, K+, hemoglobin, TSH, alkaline phosphatase, AST, ALT and urinary excretion of sodium in 24 h.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 400
Est. completion date June 2009
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- The patients studied were those with essential hypertension who could receive telephone calls to be reminded of the dates of their medical appointments and to receive guidance about hypertension

- Patients were of both genders, from any ethnic background, over 18 years old and with body mass index below 40 kg/m2, and were enrolled in the study after signing a free and informed consent term

Exclusion Criteria:

- Blood pressure < 140/90 mm Hg without antihypertensive medication

- Pregnant women or nursing mothers

- Patients with secondary hypertension

- White-coat hypertension with systolic pressure = 140 mm Hg and/or diastolic pressure = 90 mm Hg at the doctor's office and awake mean systolic pressure < 135 mm Hg or awake mean diastolic pressure < 85 mm Hg without antihypertensive medication

- Malignant hypertension

- Presence of liver dysfunction evidenced by the patient's clinical history or by one of the liver function tests with levels twice the normal values (alkaline phosphatase, total bilirubin, aspartate aminotransferase)

- Patients with clinical conditions that might interfere with the total conformity with the study or those who might have increased risk for participating in the study

- Patients with previous history of hypersensitivity reaction to the study medications

- Patients with a history of alcoholism, drug abuse or mental disorders that might invalidate the free and informed consent or limit the patient's ability to meet the protocol rules

- Patients who had participated in any other studies involving investigational drugs or drugs already marketed within the previous month, before enrollment in this study or concomitantly with this study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
phone call
patients received or not phone calls to give orientation abou treatment
Drug:
amlodipine (calcium chanel blocker) and losartan (at1 antagonist)
2,5 mg tid and 25 mg tid
atenolol (beta blocker) and hydrochlorothiazide (diuretic)
25 mg tid and 12,5 mg tid

Locations

Country Name City State
Brazil Sao Paulo University Sao Paulo
Brazil University of Sao Paulo Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood pressure control 1 year Yes
See also
  Status Clinical Trial Phase
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT05997303 - Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT03918486 - Caretaker vs. Routine Blood Pressure Sphygmomanometer
Completed NCT03410342 - The Effects of Types of Fruits and Vegetables on Vascular Function N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT04087070 - Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
Completed NCT03294928 - Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers N/A
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03997461 - Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device N/A
Completed NCT03290716 - Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China N/A
Recruiting NCT06460233 - Blood Pressure Changes After Bariatric Surgery
Recruiting NCT05196048 - Blood Pressure Sensor of Watch-type Device With ECG Technology
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Completed NCT02924454 - Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol. Phase 4
Completed NCT02451059 - Reducing Socioeconomic Disparities in Health at Pediatric Visits N/A
Active, not recruiting NCT02670967 - Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials N/A
Completed NCT02239744 - Intervention Study on the Health Impact of Air Filters in Chinese Adults N/A
Completed NCT02271633 - Nitrate Supplementation; Source Phase 4